WO2023124924A1 - 一种盐酸平阳霉素原料药中残留溶剂的检测方法 - Google Patents
一种盐酸平阳霉素原料药中残留溶剂的检测方法 Download PDFInfo
- Publication number
- WO2023124924A1 WO2023124924A1 PCT/CN2022/138249 CN2022138249W WO2023124924A1 WO 2023124924 A1 WO2023124924 A1 WO 2023124924A1 CN 2022138249 W CN2022138249 W CN 2022138249W WO 2023124924 A1 WO2023124924 A1 WO 2023124924A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solution
- residual solvent
- pingyangmycin
- reference substance
- crude drug
- Prior art date
Links
- 239000013557 residual solvent Substances 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims abstract description 26
- NRVKJXFKQWUKCB-UHFFFAOYSA-N [2-[2-[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[[5-[[1-[2-[4-[4-[3-(4-aminobutylamino)propylcarbamoyl]-1,3-thiazol-2-yl]-1,3-thiazol-2-yl]ethylamino]-3-hydroxy-1-oxobutan-2-yl]amino]-3- Chemical compound Cl.N=1C(C=2SC=C(N=2)C(=O)NCCCNCCCCN)=CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C NRVKJXFKQWUKCB-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 229940079593 drug Drugs 0.000 title claims abstract description 20
- 239000000243 solution Substances 0.000 claims abstract description 37
- 238000012360 testing method Methods 0.000 claims abstract description 34
- 238000001514 detection method Methods 0.000 claims abstract description 16
- 238000002347 injection Methods 0.000 claims abstract description 9
- 239000007924 injection Substances 0.000 claims abstract description 9
- 239000012490 blank solution Substances 0.000 claims abstract description 8
- 238000010812 external standard method Methods 0.000 claims abstract description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 51
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 44
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 34
- 239000013558 reference substance Substances 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000011550 stock solution Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000012085 test solution Substances 0.000 claims description 6
- 238000010790 dilution Methods 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 4
- 239000012088 reference solution Substances 0.000 claims description 4
- 238000005070 sampling Methods 0.000 claims description 4
- 238000004817 gas chromatography Methods 0.000 claims description 3
- 238000004364 calculation method Methods 0.000 claims description 2
- 238000011067 equilibration Methods 0.000 claims 2
- 238000004458 analytical method Methods 0.000 abstract description 2
- 230000035945 sensitivity Effects 0.000 abstract description 2
- 238000010438 heat treatment Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
- 239000012488 sample solution Substances 0.000 abstract 1
- 239000007789 gas Substances 0.000 description 15
- 239000002994 raw material Substances 0.000 description 11
- 239000003960 organic solvent Substances 0.000 description 10
- 238000005259 measurement Methods 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 230000014759 maintenance of location Effects 0.000 description 7
- 239000012159 carrier gas Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 108700004675 bleomycetin Proteins 0.000 description 3
- QYOAUOAXCQAEMW-UTXKDXHTSA-N bleomycin A5 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCNCCCCN)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QYOAUOAXCQAEMW-UTXKDXHTSA-N 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 108010006654 Bleomycin Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 238000009529 body temperature measurement Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940121657 clinical drug Drugs 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000000581 reactive spray deposition Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010061924 Pulmonary toxicity Diseases 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 231100000374 pneumotoxicity Toxicity 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/64—Electrical detectors
- G01N30/68—Flame ionisation detectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/86—Signal analysis
- G01N30/8675—Evaluation, i.e. decoding of the signal into analytical information
- G01N30/8679—Target compound analysis, i.e. whereby a limited number of peaks is analysed
Definitions
- the invention belongs to the field of drug analysis and detection, in particular to a method for detecting residual solvents in pingyangmycin hydrochloride raw materials.
- Pingyangmycin is a bleomycin anti-tumor antibiotic independently developed by my country, and its chemical structure is the bleomycin A5 component. It is mainly used for the treatment of lip cancer, tongue cancer, tooth mark cancer, nasopharyngeal cancer and other neck squamous cell carcinoma, and its lung toxicity is lower than that of bleomycin, it does not inhibit the immune function of the body, and it does not have the symptoms of leukopenia caused by commonly used anticancer drugs. In 1994, it entered the first batch of national essential drug catalogues, and its quality standards were recorded in the "Chinese Pharmacopoeia".
- This type of antibiotic is mainly produced through microbial fermentation process or semi-synthetic process, and the components are relatively complex.
- organic solvents are often used to crystallize and purify the crude pingyangmycin hydrochloride. If the process parameters are not strictly controlled, there may be residual organic solvents in the finished product. Possibly, when the residual solvent level in the medicine is higher than the safe value, it will cause harm to the human body or the environment,
- Methanol, acetone and isopropanol are used in the preparation of raw materials, but there is no report on the determination of residual organic solvents in pingyangmycin hydrochloride raw materials.
- the object of the present invention is to provide a kind of detection method of residual solvent in the pingyangmycin hydrochloride bulk drug for the above problem, comprising the following steps:
- the mixed reference solution and the test solution were heated and balanced, they were injected into the gas chromatograph by means of headspace sampling, and the chromatogram was recorded, and the residual solvent content was calculated by the peak area according to the external standard method;
- the gas chromatography conditions are:
- Chromatographic column temperature the initial column temperature is 40°C, maintained for 2 minutes, raised to 100°C at a rate of 5°C per minute, maintained for 8 minutes, then raised to 200°C at a rate of 20°C per minute, maintained for 5 minutes;
- Injection port temperature 200°C;
- the carrier gas is nitrogen, and the flow rate is 4 mL/min or 5 mL/min or 6 mL/min.
- the chromatographic column is DB-WAX, 30m ⁇ 0.32mm ⁇ 0.25 ⁇ m or DB-624, 30m ⁇ 0.53mm ⁇ 3 ⁇ m or DB-FFAP, 30m ⁇ 0.32mm ⁇ 0.5 ⁇ m).
- the blank solution is water.
- the preparation of the test product solution accurately weigh 0.2 g of the test product, put it in a headspace bottle, accurately add 2 mL of water to dissolve it, seal it, and obtain it.
- the calculation formula of the external standard method is
- A is the content of residual solvent
- B is the sample volume of the test sample
- C is the dilution multiple of the test sample
- D is the peak area of the test solution
- E is the sample volume of the reference substance
- F is the dilution multiple of the reference substance
- G is the average peak area of the reference substance.
- the present invention establishes a gas chromatography-headspace sampling method for simultaneously determining the content of three organic solvents in pingyangmycin hydrochloride bulk drug, the method is simple, accurate and highly sensitive, meets the requirements for residual solvent detection, and is suitable for pingyangmycin hydrochloride bulk drug Daily detection of residual solvents in the drug, and at the same time provide reference and basis for the revision of the residual solvent inspection items in the quality standard of this product, effectively improve the quality of raw materials and reduce the risk of clinical drug use.
- Fig. 1 is a system suitability chromatogram
- Fig. 2 is blank solution chromatogram
- Fig. 3 is need testing solution chromatogram
- Fig. 4 is methanol linear relationship diagram
- Fig. 5 is acetone linear relationship diagram
- Fig. 6 is isopropanol linear relationship figure
- Reagent raw material of pingyangmycin hydrochloride, batch number: Y190401, Y200901, Y200902, 200322;
- Programmed temperature rise the initial column temperature is 40°C, maintained for 2 minutes, raised to 100°C at a rate of 5°C per minute, maintained for 8 minutes, then raised to 200°C at a rate of 20°C per minute, maintained for 5 minutes;
- Injection port temperature 200°C;
- Carrier gas nitrogen; flow rate: 5ml/min.
- Mixed reference substance stock solution Accurately weigh 1.5089g of methanol, 2.5086g of acetone, and 2.5078g of isopropanol, put them in a 50ml measuring bottle, dilute to the mark with water, shake well, and contain 3mg/mL of methanol, acetone, and isopropanol respectively , 5mg/mL and 5mg/mL mixed reference substance stock solution.
- Reference substance solution Accurately measure 5mL of the mixed reference substance stock solution, put it in a 50mL measuring bottle, add water to dilute to the mark, and shake well to obtain the mixed reference substance solution
- Test product solution Accurately weigh 0.2 g of the test product, put it in a headspace bottle, accurately add 2 mL of water to dissolve it, seal it, and obtain it.
- the peak area RSDs of the 6 measurements of the quantitative limits of methanol, acetone and isopropanol are 1.7%, 1.3%, and 1.4%, respectively, and the quantitative limits are 18.107 ⁇ g, 1.505 ⁇ g, and 3.494 ⁇ g, respectively.
- the detection limits were 6.036 ⁇ g, 0.501 ⁇ g, and 1.026 ⁇ g, respectively.
- Standard addition solution Accurately measure 2.5ml, 5.0ml, 7.5ml of the mixed standard stock solution, put it in a 50ml measuring bottle, add water to dilute to the mark, and shake well to obtain the standard addition solution (1), (2), (3);
- Test solution Accurately weigh about 0.2 g of this product (batch number: Y190401), 9 parts in total, divide into 3 groups, put them in headspace bottles, add 2.0 ml of the above-mentioned mixed control solution, and seal. Take the above solution and inject it into a gas chromatograph, and record the chromatogram; the ratio of the measured amount to the added amount is the recovery rate.
- methanol retention time RSD is 0.01%
- peak area RSD is 1.0%
- acetone retention time RSD is 0.0%
- peak area RSD is 0.7%
- isopropanol retention time RSD is 0.01%
- peak area RSD is 0.8 %
- the injection precision is good.
- this patent establishes a method for the simultaneous determination of three organic solvents in pingyangmycin hydrochloride raw material by gas chromatography-headspace sampling.
- the method is simple, accurate, and highly sensitive.
- the daily detection of residual solvents in Pingyangmycin raw materials also provides reference and basis for the revision of the residual solvent inspection items in the quality standard of this product, effectively improving the quality of raw materials and reducing the risk of clinical drug use.
- the carrier gas flow rate is different, and the rest are the same as the conditions in the above-mentioned examples.
- the temperature of the injection port is different, and the rest are the same as the conditions in the above-mentioned examples.
- the detector temperature is different, and the rest is the same as the conditions in the above-mentioned examples.
- the split ratio is different, and the remainder is the same as in embodiment 1.
- the control solution was injected into the gas chromatograph, and the chromatographic retention behavior of the three organic solvents under the condition of split ratio 5:1 and 10:1 was investigated.
- the separation degree of each component and the number of theoretical plates were used as evaluation indicators.
- the measurement results are shown in Table 13. The three solvents could achieve baseline separation under all chromatographic conditions.
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Library & Information Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明涉及药物分析检测领域,提供了一种盐酸平阳霉素原料药中残留溶剂的检测方法。本发明包括以下步骤:分别将空白溶液、混合对照品溶液和供试品溶液加热平衡后,采用顶空进样的方式注入到气相色谱仪中,记录色谱图,按外标法以峰面积计算残留溶剂的含量。本发明方法简单、准确、灵敏度高,符合残留溶剂检测要求,适用于盐酸平阳霉素原料药中残留溶剂的日常检测,同时为本品质量标准中残留溶剂检查项的修订提供参考和依据,有效提高原料药质量,降低临床用药风险。
Description
本发明属于药物分析检测领域,具体是一种盐酸平阳霉素原料药中残留溶剂的检测方法。
平阳霉素是由我国自主研发的博来霉素类抗肿瘤抗生素,其化学结构为博来霉素A5组分。主治唇癌、舌癌、齿痕癌、鼻咽癌等颈部鳞癌,且肺毒性低于博来霉素,不抑制机体的免疫功能,无常用抗癌药物所引起的白细胞减少症状。1994年进入首批国家基本药物目录,其质量标准收载于《中国药典》。
这类抗生素主要通过微生物发酵工艺或半合成过程生产,组分较复杂,生产工艺中常用有机溶剂对盐酸平阳霉素粗品进行结晶提纯提纯,如果工艺参数控制不严格,存在成品中残留有机溶剂的可能,当药品中残留溶剂水平高于安全值时,就会对人体或环境产生危害,
在原料药制备过程中使用甲醇、丙酮和异丙醇3种溶剂,但是目前国内尚未有测定盐酸平阳霉素原料药中有机溶剂残留量的报道。
根据人用药物注册技术要求国际协调会(ICH)和中国药典2020年版通则0861“残留溶剂测定法”的规定,上述3种溶剂均有残留量限度要求。为了有效控制盐酸平阳霉素原料质量,保证用药安全,本文建立气相色谱法测定盐酸平阳霉素中3种有机残留溶剂的方法,灵敏度高,重复性好,且简单易操作,适合用于盐酸平阳霉素中上述3种有机溶剂的残留量的测定,为该原料药的质量控制提供参考。盐酸平阳霉素收载《中国药典》2020年版,现行质量标准中无残留溶剂检查项,无法全面控制产品质量。
发明内容
本发明的目的是针对以上问题,提供了一种盐酸平阳霉素原料药中残留溶剂的检测方法,包括以下步骤:
分别将空白溶液、混合对照品溶液和供试品溶液加热平衡后,采用顶空进样的方式注入到气相色谱仪中,记录色谱图,按外标法以峰面积计算残留溶剂的含量;
气相色谱的条件为:
色谱柱温度:起始柱温为40℃,维持2分钟,以每分钟5℃的速率升温至100℃,维持8分钟,再以每分钟20℃的速率升温至200℃,维持5分钟;
进样口温度:200℃;
检测器温度:250℃;
顶空瓶平衡温度:70℃,平衡时间:30分钟;
载气为氮气,流速为4mL/min或5mL/min或6mL/min。优选的,所述色谱柱为DB-WAX,30m×0.32mm×0.25μm或DB-624,30m×0.53mm×3μm或DB-FFAP,30m×0.32mm×0.5μm)。
优选的,所述空白溶液为水。
优选的,所述供试品溶液的制备:精密称取供试品0.2g,置顶空瓶中,精密加入水2mL溶解,密封,即得。
优选的,所述混合对照品溶液的制备:
(1)精密称取甲醇1.5089g、丙酮2.5086g、异丙醇2.5078g,置50ml量瓶中,用水稀释至刻度,摇匀,含甲醇、丙酮、异丙醇分别为3mg/mL、5mg/mL和5mg/mL的混合对照品贮备液;
(2)精密量取混合对照品贮备液5mL,置50mL量瓶中,加水稀释至刻度,摇匀,即得混合对照品溶液。
优选的,所述外标法的计算公式为
其中A为残留溶剂的含量,B为供试品称样量,C为供试品稀释倍数,D为供试品溶液峰面积,E为对照品称样量,F为对照品稀释倍数,G为对照品平均峰面积。
与现有技术相比,本发明的有益效果如下:
本发明建立了气相色谱-顶空进样同时测定盐酸平阳霉素原料药中3种有机溶剂含量的方法,方法简单、准确、灵敏度高,符合残留溶剂检测要求,适用于盐酸平阳霉素原料药中残留溶剂的日常检测,同时为本品质量标准中残留溶剂检查项的修订提供参考和依据,有效提高原料药质量,降低临床用药风险。
图1为系统适用性色谱图;
图2为空白溶液色谱图;
图3为供试品溶液色谱图;
图4为甲醇线性关系图;
图5为丙酮线性关系图;
图6为异丙醇线性关系图;
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
1.仪器与试剂
仪器:安捷伦7890B气相色谱仪;
氢火焰离子化检测器(FID);
纯水氢气发生器(济南浩伟实验仪器有限公司);
SGK-2LB低噪空气泵(北京东方精华苑科技有限公司);
Open LBACDS Chem Station Edition工作站;
德国梅特勒XS205电子分析天平。
试剂:盐酸平阳霉素原料,批号:Y190401、Y200901、Y200902、200322;
甲醇、丙酮、异丙醇均为色谱纯。
2.色谱条件
色谱柱:DB-WAX(30m×0.32mm×0.25μm);
DB-624(30m×0.53mm×3μm);
DB-FFAP(30m×0.32mm×0.5μm)。
程序升温:起始柱温为40℃,维持2分钟,以每分钟5℃的速率升温至100℃,维持8分钟,再以每分钟20℃的速率升温至200℃,维持5分钟;
进样口温度:200℃;
检测器温度:250℃;
顶空瓶平衡温度:70℃,平衡时间:30分钟;
载气:氮气;流速:5ml/min。
3.溶液配制
空白溶液:水
混合对照品贮备液:精密称取甲醇1.5089g、丙酮2.5086g、异丙醇2.5078g,置50ml量瓶中,用水稀释至刻度,摇匀,含甲醇、丙酮、异丙醇分别为3mg/mL、5mg/mL和5mg/mL的混合对照品贮备液。
对照品溶液:精密量取混合对照品贮备液5mL,置50mL量瓶中,加水稀释至刻度,摇匀,即得混合对照品溶液
供试品溶液:精密称取供试品0.2g,置顶空瓶中,精密加入水2mL溶解,密封,即得。
4.方法学验证
4.1专属性试验
取混合对照品溶液、空白溶液和供试品溶液各分别注入气相色谱仪,记录色谱图。结果如附图1-3所示。
结果表明,在该色谱条件下,出峰顺序依次为:甲醇、丙酮和异丙醇,各成分峰均能达到基线分离,分离度大于1.8;理论板数以丙酮峰计为50507,溶剂对样品测定无干扰,其他杂质峰和主峰分离良好。
4.2检出限及定量限试验
精密量取混合对照品逐级稀释直至信噪比s/n约10,即为定量限溶液。
精密量取定量限溶液3ml,置10ml量瓶,加水稀释至刻度,摇匀,即为检出限溶液。
取定量限溶液注入气相色谱仪,连续测定6次,记录色谱图。
表1定量限试验
由上述试验结果可知:甲醇、丙酮和异丙醇定量限6次测定结果的峰面积RSD分别为1.7%,1.3%,1.4%,定量限分别为18.107μg,1.505μg,3.494μg。检出限分别为6.036μg,0.501μg,1.026μg。
4.3线性关系考察
精密吸取混合对照品贮备液各0.01ml,1ml,5ml,10ml,20ml,50ml,分别置于100mL量瓶中,加水稀释至刻度,摇匀,制成系列对照品溶液。按上述色谱条件进样测定,记录峰面积。
表2甲醇线性关系试验
以峰面积为纵坐标,以浓度为横坐标进行线性回归,线性关系图如附图4所示:
甲醇在0.0003mg/ml~1.5089mg/ml范围内,线性方程为y=1364x-2.149,相关系数r=1.0000,峰面积A与浓度C(mg/ml)呈显著线性关系。
表3丙酮线性关系试验
以峰面积为纵坐标,以浓度为横坐标进行线性回归,线性关系图如附图5所示,
丙酮在0.0005mg/ml~2.5086mg/ml范围内,线性方程为y=9824x-61.80,相关系数r=0.9995,峰面积A与浓度C(mg/ml)呈显著线性关系。
表4异丙醇线性关系试验
以峰面积为纵坐标,以浓度为横坐标进行线性回归,线性关系图如附图6所示,
异丙醇在0.0005mg/ml~2.5018mg/ml范围内,线性方程为Y=5518x-3.563,相关系数r=1.0000,峰面积A与浓度C(mg/ml)呈显著线性 关系。
4.4准确度试验
标准加入溶液:精密量取混合标准贮备液2.5ml、5.0ml、7.5ml置50ml量瓶中,加水稀释至刻度,摇匀,即得标准加入液(1)、(2)、(3);
供试品溶液:精密称取本品(批号:Y190401)约0.2g,共9份,分3组,置顶空瓶中,分别加入上述混合对照溶液2.0ml,密封。取上述溶液注入气相色谱仪,记录色谱图;测得量与加入量的比值即为回收率。
表5回收率试验
由以上试验结果可知:甲醇、丙酮和异丙醇回收率范围分别为100.3%~105.6%(RSD%=2.8),102.1%~102.9%(RSD%=0.6),100.2%~102.1%(RSD%=1.1),回收率良好,证明本法准确性良好,符合验证要求。
4.5精密度试验
4.5.1进样精密度试验
取对照品溶液注入气相色谱仪,记录色谱图。重复进样6次,计算RSD,考察本法的仪器精密度。
表6进样精密度试验
由试验结果可知:甲醇保留时间RSD为0.01%,峰面积RSD为1.0%,丙酮保留时间RSD为0.0%,峰面积RSD为0.7%,异丙醇保留时间RSD为0.01%,峰面积RSD为0.8%,进样精密度良好。
4.5.2重复性试验
取盐酸平阳霉素原料1批(批号:Y190401)和混合对照品贮备溶液,照拟定方法,平行制备6份,分别注入气相色谱仪,记录色谱图。考察本法的重复性。
表7重复性试验结果
结论:同一实验人员重复测定6次,6次测定结果比较甲醇、丙酮、异丙醇的检出量一致。方法重复性良好。
4.5.3中间精密度试验
不同实验人员按对照品溶液和供试品溶液操作,配制对照品溶液6份和供试品(批号:Y190401)溶液6份。分别注入气相色谱仪,记录色谱图。
表8中间精密度试验结果
结论:不同实验人员重复测定6次,6次测定结果比较,甲醇、丙酮和异丙醇检出量一致。方法重复性良好。
4.6溶液稳定性试验
按对照品溶液配制方法制备,于室温放置0、1、2、3、4、5、6小时,取不同放置时间的上述溶液注入气相色谱仪,记录色谱图。
表9对照品与供试品溶液稳定性试验结果
由试验结果可知:室温放置6小时,对照品溶液中甲醇、丙酮和异丙醇峰面积RSD分别为4.1%,1.6%,1.9%(n=6),对照品溶液在6小时内稳定。
综上所述,本专利建立了气相色谱-顶空进样同时测定盐酸平阳霉素原料 药中3种有机溶剂含量的方法,方法简单、准确、灵敏度高,符合残留溶剂检测要求,适用于盐酸平阳霉素原料药中残留溶剂的日常检测,同时为本品质量标准中残留溶剂检查项的修订提供参考和依据,有效提高原料药质量,降低临床用药风险。
(二)对比例1
载气流速不同,余同上述实施例中的条件。取对照溶液注入气相色谱仪,考察载气流速4mL/min、5mL/min、6mL/min条件下3种有机溶剂的色谱保留行为,以各组分分离度和理论塔板数为评价指标,测定结果见表10。结果在各色谱条件下3种溶剂均可达到基线分离。
表10不同载气流速测定结果
(三)对比例2
进样口温度不同,余同上述实施例中的条件。
取对照溶液注入气相色谱仪,考察进样口温度200℃、220℃、240℃条件下3种有机溶剂的色谱保留行为,以各组分分离度和理论塔板数为评价指标,测定结果见表11。在各色谱条件下3种溶剂均可达到基线分离。
表11不同进样口温度测定结果
(四)对比例3
检测器温度不同,余同上述实施例中的条件。
取对照溶液注入气相色谱仪,考察检测器温度230℃、250℃、270℃条件下3种有机溶剂的色谱保留行为,以各组分分离度和理论塔板数为评价指标,测定结果见表12。在各色谱条件下3种溶剂均可达到基线分离。
表12不同检测器温度测定结果
(五)对比例3
分流比不同,余同实施例1。
取对照溶液注入气相色谱仪,考察分流比5:1、10:1条件下3种有机溶剂的色谱保留行为,以各组分分离度和理论塔板数为评价指标,测定结果见表13。在各色谱条件下3种溶剂均可达到基线分离。
表13不同分流比测定结果
需要说明的是,在本文中,诸如第一和第二等之类的关系术语仅仅用来将一个实体或者操作与另一个实体或操作区分开来,而不一定要求或者暗示这些实体或操作之间存在任何这种实际的关系或者顺序。而且,术语“包括”、“包含”或者其任何其他变体意在涵盖非排他性的包含,从而使得包括一系列要素的过程、方法、物品或者设备不仅包括那些要素,而且还包括没有明确列出的其他要素,或者是还包括为这种过程、方法、物品或者设备所固有的要素。
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。
Claims (6)
- 一种盐酸平阳霉素原料药中残留溶剂的检测方法,其特征在于,包括以下步骤:分别将空白溶液、混合对照品溶液和供试品溶液加热平衡后,采用顶空进样的方式注入到气相色谱仪中,记录色谱图,按外标法以峰面积计算残留溶剂的含量;气相色谱的条件为:色谱柱温度:起始柱温为40℃,维持2分钟,以每分钟5℃的速率升温至100℃,维持8分钟,再以每分钟20℃的速率升温至200℃,维持5分钟;进样口温度:200℃;检测器温度:250℃;顶空瓶平衡温度:70℃,平衡时间:30分钟。
- 根据权利要求1所述的一种盐酸平阳霉素原料药中残留溶剂的检测方法,其特征在于,所述色谱柱为DB-WAX,30m×0.32mm×0.25μm或DB-624,30m×0.53mm×3μm或DB-FFAP,30m×0.32mm×0.5μm。
- 根据权利要求1所述的一种盐酸平阳霉素原料药中残留溶剂的检测方法,其特征在于,所述空白溶液为水。
- 根据权利要求1所述的一种盐酸平阳霉素原料药中残留溶剂的检测方法,其特征在于,所述供试品溶液的制备:精密称取供试品0.2g,置顶空瓶中,精密加入水2mL溶解,密封,即得。
- 根据权利要求1所述的一种盐酸平阳霉素原料药中残留溶剂的检测方法,其特征在于,所述混合对照品溶液的制备:(1)精密称取甲醇1.5089g、丙酮2.5086g、异丙醇2.5078g,置50ml量瓶中,用水稀释至刻度,摇匀,含甲醇、丙酮、异丙醇分别为3mg/mL、5mg/mL和5mg/mL的混合对照品贮备液;(2)精密量取混合对照品贮备液5mL,置50mL量瓶中,加水稀释至刻 度,摇匀,即得混合对照品溶液。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111677697.2A CN114527203A (zh) | 2021-12-31 | 2021-12-31 | 一种盐酸平阳霉素原料药中残留溶剂的检测方法 |
CN202111677697.2 | 2021-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023124924A1 true WO2023124924A1 (zh) | 2023-07-06 |
Family
ID=81620916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/138249 WO2023124924A1 (zh) | 2021-12-31 | 2022-12-10 | 一种盐酸平阳霉素原料药中残留溶剂的检测方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114527203A (zh) |
WO (1) | WO2023124924A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114527203A (zh) * | 2021-12-31 | 2022-05-24 | 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) | 一种盐酸平阳霉素原料药中残留溶剂的检测方法 |
CN115561353A (zh) * | 2022-09-22 | 2023-01-03 | 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) | 一种测定马来酸甲麦角片剂中乙醇量的方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007055362A1 (ja) * | 2005-11-14 | 2007-05-18 | Daiichi Sankyo Company, Limited | ポリペプチドの検出又は定量方法、及び装置 |
CN105388242A (zh) * | 2015-11-11 | 2016-03-09 | 江苏康缘药业股份有限公司 | 二对甲苯磺酸缘生替尼原料药中残留溶剂的检测方法 |
CN108614058A (zh) * | 2018-06-19 | 2018-10-02 | 广西壮族自治区食品药品检验所 | 测定甘氨酸原料药中有机溶剂残留量的顶空气相色谱法 |
CN111060628A (zh) * | 2019-12-31 | 2020-04-24 | 卓和药业集团有限公司 | 他克莫司残留溶剂的检测方法 |
CN111089911A (zh) * | 2018-10-24 | 2020-05-01 | 江苏和成显示科技有限公司 | 光电显示材料中残留溶剂的检测方法 |
CN112611820A (zh) * | 2020-12-31 | 2021-04-06 | 武汉九州钰民医药科技有限公司 | 奥扎格雷钠残留溶剂的测定方法 |
CN112710758A (zh) * | 2020-12-24 | 2021-04-27 | 山东省药学科学院 | 一种盐酸他喷他多原料药中残留溶剂的检测方法 |
CN113607843A (zh) * | 2021-07-30 | 2021-11-05 | 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) | 一种检测西罗莫司原料药中残留溶剂的方法 |
CN114527203A (zh) * | 2021-12-31 | 2022-05-24 | 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) | 一种盐酸平阳霉素原料药中残留溶剂的检测方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110208428A (zh) * | 2019-07-08 | 2019-09-06 | 苏州天马药业有限公司 | 一种硫酸氢氯吡格雷原料药中多种残留溶剂的气相检测方法 |
-
2021
- 2021-12-31 CN CN202111677697.2A patent/CN114527203A/zh active Pending
-
2022
- 2022-12-10 WO PCT/CN2022/138249 patent/WO2023124924A1/zh unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007055362A1 (ja) * | 2005-11-14 | 2007-05-18 | Daiichi Sankyo Company, Limited | ポリペプチドの検出又は定量方法、及び装置 |
CN105388242A (zh) * | 2015-11-11 | 2016-03-09 | 江苏康缘药业股份有限公司 | 二对甲苯磺酸缘生替尼原料药中残留溶剂的检测方法 |
CN108614058A (zh) * | 2018-06-19 | 2018-10-02 | 广西壮族自治区食品药品检验所 | 测定甘氨酸原料药中有机溶剂残留量的顶空气相色谱法 |
CN111089911A (zh) * | 2018-10-24 | 2020-05-01 | 江苏和成显示科技有限公司 | 光电显示材料中残留溶剂的检测方法 |
CN111060628A (zh) * | 2019-12-31 | 2020-04-24 | 卓和药业集团有限公司 | 他克莫司残留溶剂的检测方法 |
CN112710758A (zh) * | 2020-12-24 | 2021-04-27 | 山东省药学科学院 | 一种盐酸他喷他多原料药中残留溶剂的检测方法 |
CN112611820A (zh) * | 2020-12-31 | 2021-04-06 | 武汉九州钰民医药科技有限公司 | 奥扎格雷钠残留溶剂的测定方法 |
CN113607843A (zh) * | 2021-07-30 | 2021-11-05 | 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) | 一种检测西罗莫司原料药中残留溶剂的方法 |
CN114527203A (zh) * | 2021-12-31 | 2022-05-24 | 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) | 一种盐酸平阳霉素原料药中残留溶剂的检测方法 |
Also Published As
Publication number | Publication date |
---|---|
CN114527203A (zh) | 2022-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2023124924A1 (zh) | 一种盐酸平阳霉素原料药中残留溶剂的检测方法 | |
CN113607843A (zh) | 一种检测西罗莫司原料药中残留溶剂的方法 | |
CN111751459A (zh) | 一种同时检测西他沙星中多种残留溶剂的方法 | |
CN104122363A (zh) | 一种甲钴胺片有关物质的测定方法 | |
WO2023124923A1 (zh) | 一种马来酸甲麦角新碱原料中成盐率的测定方法 | |
CN107703233A (zh) | 一种腺苷含量的检测方法 | |
CN115356420A (zh) | 一种基于一测多评的蒲地蓝消炎片质量评价方法 | |
CN111551645A (zh) | 一种硫酸羟氯喹有关物质的检测方法及其应用 | |
CN111487340A (zh) | 一种奥贝胆酸原料药中有机残留溶剂的检测方法 | |
CN109580825B (zh) | 消旋卡多曲中对甲苯磺酸酯类物质的检测方法 | |
CN103926350A (zh) | 康复新液制剂指纹图谱的检查方法及标准指纹图谱 | |
CN106198819A (zh) | 顶空气相色谱法测定西格列汀原料药中残留溶剂的方法 | |
CN103323541B (zh) | 肝素钠封管注射液的质量检测方法 | |
CN102590408B (zh) | 一种冠心宁注射液中大分子物质的检测方法 | |
CN112684031B (zh) | 聚维酮k30含量的hplc测定方法 | |
CN111426760B (zh) | 一种多索茶碱原料药中基因毒性杂质的测定方法 | |
CN110187021B (zh) | 一种同时测定氯氰碘柳胺钠伊维菌素注射液中两种主药含量的方法 | |
CN113063881A (zh) | 一种恩替卡韦口服溶液有关物质分析方法 | |
CN113030323A (zh) | 一种尼洛替尼原料药中残留溶剂的检测方法 | |
CN111380992A (zh) | 一种检测福莫特罗原料药中有机溶剂残留量的方法 | |
CN100401057C (zh) | 复方芦荟胶囊中芦荟苷的检测方法 | |
CN102233094B (zh) | 参麦注射液有效成分测定方法 | |
CN110849995B (zh) | 吲达帕胺原料药中dcu的检测方法 | |
CN112326860B (zh) | 同时检测原料药或制剂中1,4-二氯丁烷和1-氯-4-羟基丁烷遗传毒性杂质的方法 | |
CN115420840B (zh) | 一种水合氯醛有关物质检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22914179 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |